Verdict
Medvi runs a compounded-semaglutide and tirzepatide model at flat monthly pricing, with no lock-in and rapid intake. Comparable to Henry Meds and Mochi on price; less established clinical depth than Form Health or Knownwell. Best fit for cash-pay patients who want predictable monthly cost with minimal friction.
Pros
- Flat $179/mo compounded semaglutide at entry dose, $299/mo for tirzepatide.
- Month-to-month cancellation with no fee.
- Two-day average time to first prescription via async intake.
- No supplement upsells in member feedback.
- Named partner pharmacies disclosed at intake.
Cons
- Compounded only, no insurance pathway for branded GLP-1.
- Transactional model with limited between-visit support.
- Higher titration doses run $199-$299/mo, the headline price does not hold.
- Newer brand than Henry Meds or Mochi, shorter operating track record.
- Not available in Louisiana or Mississippi.
- Flat pricing at every dose
- Fast 24-48 hour intake
- No supplement upsells
- Transactional model; limited between-visit support
- Compounded-only; no insurance for branded GLP-1
- Newer brand than Mochi or Henry Meds
Best for
- Cash-pay patients who want flat predictable compounded GLP-1 pricing with no lock-in and same-week onboarding. Strong fit if you've taken GLP-1 before and want a simple ongoing prescription channel.
Not for
- Insurance-pathway shoppers, patients with multiple comorbidities needing clinical depth or anyone wanting branded Wegovy or Zepbound through standard PA.
Pricing
$179/mo for compounded semaglutide at entry dose. Higher titration doses $199-$299/mo. Tirzepatide tier $299/mo flat. Includes consultation and medication shipping.
Lock-in & cancellation
Month-to-month
No annual commitment. Cancel anytime online with no fee.
How to cancel: Month-to-month, no annual commitment, cancel anytime online with no fee; billed every 28 days.
Medication options
Sourced from named 503A compounding pharmacies disclosed at intake.
The FDA officially removed semaglutide from the drug-shortage list in February 2025, which narrowed the legal basis for routine 503A compounding of exact-copy semaglutide. Medvi addresses this by using a personalized-formulation model (the compound includes an additional active ingredient like vitamin B12) which is legally distinct from the FDA-approved product. The active GLP-1 molecule is the same; the regulatory framing is different. Some state pharmacy boards have tightened oversight in 2025-2026. For the full background see our compounded vs FDA-approved breakdown.
FDA-approved branded
- None offered
503A-compounded
- Compounded semaglutide
- Compounded tirzepatide
Other medications
- None offered
- Compounded GLP-1 carries 503A regulatory exposure; see compounded callout
Onboarding experience
Time to first prescription: 2 days.
Consultation type: Asynchronous intake review by licensed clinician.
Requirements: Medical history form, photo ID, height/weight.
Member feedback
Members praise the flat pricing and simple intake. Common complaint is limited clinical follow-up between dose changes.
What works
- Flat pricing at every dose
- Fast 24-48 hour intake
- No supplement upsells
What to watch
- Transactional model; limited between-visit support
- Compounded-only; no insurance for branded GLP-1
- Newer brand than Mochi or Henry Meds
How we scored Medvi
Five dimensions, ten points each, weighted equally. Overall is the simple average.
Transparency
Terms
Experience
Options
Outcomes
Frequently asked questions
Is Medvi cheaper than Mochi?
Does Medvi accept insurance?
Alternatives to Medvi
If Medvi isn't the right fit, here are three programs we'd consider as next options:
Learn the category before you commit
Four pieces we'd read before signing up for any GLP-1 telehealth program, Medvi included:
